Ibaflin

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

ибафлоксацин

Available from:

Intervet International BV

ATC code:

QJ01MA96

INN (International Name):

ibafloxacin

Therapeutic group:

Dogs; Cats

Therapeutic area:

Антибактериални средства за системна употреба

Therapeutic indications:

Куче:Ibaflin е показан за лечение на следните условия при кучета:кожни инфекции (пиодермите - повърхностни и дълбоки рани, абсцеси), причинени от чувствителни щамове стафилококи, pseudomonas aeruginosa и Протея мирабилис;остра, неусложнена инфекция на пикочните пътища, причинени от чувствителни щамове стафилококи, Протея видове, Энтеробактер). , Е.. coli и Klebsiella spp. ;дихателни инфекции (на горните пътища), причинени от чувствителни щамове на staphylococcus, e.. coli и Klebsiella spp. Ibaflin гел е показан кучета за лечение на следните условия:кожни инфекции (пиодермите - повърхностни и дълбоки рани, абсцеси), причинени от чувствителни микроорганизми, като стафилокок). , Е.. coli и Р. тдгаешз. Котки:Ibaflin гел откриете при котки за лечение на следните условия:кожни инфекции (меките тъкани, инфекции на РАНИ, абсцеси), причинени от чувствителни микроорганизми, като стафилокок). , Е.. coli, Proteus spp. и Pasteurella spp. ;на горните дихателни инфекции, причинени от чувствителни микроорганизми като Staphylococcus ѕрр. , Е.. coli, Klebsiella spp. и Pasteurella spp.

Product summary:

Revision: 7

Authorization status:

Отменено

Authorization date:

2000-06-13

Patient Information leaflet

                                DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
1/35
Medicinal product no longer authorised
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Ibaflin 30 mg, tablete za pse
Ibaflin 150 mg, tablete za pse
Ibaflin 300 mg, tablete za pse
Ibaflin 900 mg, tablete za pse
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena tableta Ibaflina vsebuje:
ZDRAVILNA UČINKOVINA
Ibafloksacin 30 mg
Ibafloksacin 150 mg
Ibafloksacin 300 mg
Ibafloksacin 900 mg
POMOŽNE SNOVI
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Tableta
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Psi
4.2
INDIKACIJE ZA UPORABO
Ibaflin je pri psih indiciran za zdravljenje naslednjih bolezenskih
stanj:
Dermalne okužbe (pioderma – površinska in globoka, rane, abscesi),
ki jih povzročajo občutljivi sevi
stafilokokov
_, E. coli_
in
_Proteus mirabilis_
Akutne,
nezapletene okužbe
sečil,
ki jih
povzročajo
občutljivi
sevi
stafilokokov,
_Proteus_
spp.,
_Enterobacter_
spp.,
_E. coli_
in
_Klebsiella _
spp
_. _
Okužbe
dihalnih
poti
(zgornjih),
ki
jih
povzročajo
občutljivi
sevi
stafilokokov,
_E. _
_coli_
in
_Klebsiella_
spp.
4.3
KONTRAINDIKACIJE
Zdravila ne uporabljamo pri psih v obdobju rasti, ker ima lahko
škodljiv učinek na sklepni hrustanec.
Trajanje
obdobja rasti je
različno
glede na
pasmo.
Pri
večini pasem
je
uporaba ibafloksacina
kontraindicirana za pse, mlajše od 8 mesecev in pri zelo velikih
pasmah za pse, mlajše od 18 mesecev.
Zdravila
ne
uporabljajte
v
kombinaciji
z
nesteroidnimi
protivnetnimi
zdravili
(NSAID).
Ne
uporabljajte pri psih s krči v anamnezi.
4.4
POSEBNA OPOZORILA ZA VSAKO CILJNO ŽIVALSKO VRSTO
Ne uporabite pri psih z znano preobčutljivostjo za kinolone.
2/35
Medicinal product no longer authorised
4.5
POSEBNI PREVIDNOSTNI UKREPI
Preveliko zanašanje na eno skupino antibiotikov lahko privede do
odpornosti bakterijske populacije.
Preudarno je prihraniti uporabo fluorokinolonov za zdravljenje
kliničnih stanj, ki se slabo odzivajo ali
za katera pričakujemo, da so bodo slabo odzivala na druge skupine
antib
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
1/35
Medicinal product no longer authorised
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Ibaflin 30 mg, tablete za pse
Ibaflin 150 mg, tablete za pse
Ibaflin 300 mg, tablete za pse
Ibaflin 900 mg, tablete za pse
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena tableta Ibaflina vsebuje:
ZDRAVILNA UČINKOVINA
Ibafloksacin 30 mg
Ibafloksacin 150 mg
Ibafloksacin 300 mg
Ibafloksacin 900 mg
POMOŽNE SNOVI
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Tableta
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Psi
4.2
INDIKACIJE ZA UPORABO
Ibaflin je pri psih indiciran za zdravljenje naslednjih bolezenskih
stanj:
Dermalne okužbe (pioderma – površinska in globoka, rane, abscesi),
ki jih povzročajo občutljivi sevi
stafilokokov
_, E. coli_
in
_Proteus mirabilis_
Akutne,
nezapletene okužbe
sečil,
ki jih
povzročajo
občutljivi
sevi
stafilokokov,
_Proteus_
spp.,
_Enterobacter_
spp.,
_E. coli_
in
_Klebsiella _
spp
_. _
Okužbe
dihalnih
poti
(zgornjih),
ki
jih
povzročajo
občutljivi
sevi
stafilokokov,
_E. _
_coli_
in
_Klebsiella_
spp.
4.3
KONTRAINDIKACIJE
Zdravila ne uporabljamo pri psih v obdobju rasti, ker ima lahko
škodljiv učinek na sklepni hrustanec.
Trajanje
obdobja rasti je
različno
glede na
pasmo.
Pri
večini pasem
je
uporaba ibafloksacina
kontraindicirana za pse, mlajše od 8 mesecev in pri zelo velikih
pasmah za pse, mlajše od 18 mesecev.
Zdravila
ne
uporabljajte
v
kombinaciji
z
nesteroidnimi
protivnetnimi
zdravili
(NSAID).
Ne
uporabljajte pri psih s krči v anamnezi.
4.4
POSEBNA OPOZORILA ZA VSAKO CILJNO ŽIVALSKO VRSTO
Ne uporabite pri psih z znano preobčutljivostjo za kinolone.
2/35
Medicinal product no longer authorised
4.5
POSEBNI PREVIDNOSTNI UKREPI
Preveliko zanašanje na eno skupino antibiotikov lahko privede do
odpornosti bakterijske populacije.
Preudarno je prihraniti uporabo fluorokinolonov za zdravljenje
kliničnih stanj, ki se slabo odzivajo ali
za katera pričakujemo, da so bodo slabo odzivala na druge skupine
antib
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 24-06-2010
Public Assessment Report Public Assessment Report Spanish 29-11-2007
Patient Information leaflet Patient Information leaflet Czech 24-06-2010
Public Assessment Report Public Assessment Report Czech 29-11-2007
Patient Information leaflet Patient Information leaflet Danish 24-06-2010
Public Assessment Report Public Assessment Report Danish 29-11-2007
Patient Information leaflet Patient Information leaflet German 24-06-2010
Public Assessment Report Public Assessment Report German 29-11-2007
Patient Information leaflet Patient Information leaflet Estonian 24-06-2010
Public Assessment Report Public Assessment Report Estonian 29-11-2007
Patient Information leaflet Patient Information leaflet Greek 24-06-2010
Public Assessment Report Public Assessment Report Greek 29-11-2007
Patient Information leaflet Patient Information leaflet English 24-06-2010
Public Assessment Report Public Assessment Report English 29-11-2007
Patient Information leaflet Patient Information leaflet French 24-06-2010
Public Assessment Report Public Assessment Report French 29-11-2007
Patient Information leaflet Patient Information leaflet Italian 24-06-2010
Public Assessment Report Public Assessment Report Italian 29-11-2007
Patient Information leaflet Patient Information leaflet Latvian 24-06-2010
Public Assessment Report Public Assessment Report Latvian 29-11-2007
Patient Information leaflet Patient Information leaflet Lithuanian 24-06-2010
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-06-2010
Public Assessment Report Public Assessment Report Lithuanian 29-11-2007
Patient Information leaflet Patient Information leaflet Hungarian 24-06-2010
Summary of Product characteristics Summary of Product characteristics Hungarian 24-06-2010
Public Assessment Report Public Assessment Report Hungarian 29-11-2007
Patient Information leaflet Patient Information leaflet Maltese 24-06-2010
Public Assessment Report Public Assessment Report Maltese 29-11-2007
Patient Information leaflet Patient Information leaflet Dutch 24-06-2010
Public Assessment Report Public Assessment Report Dutch 29-11-2007
Patient Information leaflet Patient Information leaflet Polish 24-06-2010
Public Assessment Report Public Assessment Report Polish 29-11-2007
Patient Information leaflet Patient Information leaflet Portuguese 24-06-2010
Summary of Product characteristics Summary of Product characteristics Portuguese 24-06-2010
Public Assessment Report Public Assessment Report Portuguese 29-11-2007
Patient Information leaflet Patient Information leaflet Romanian 24-06-2010
Public Assessment Report Public Assessment Report Romanian 29-11-2007
Patient Information leaflet Patient Information leaflet Slovak 24-06-2010
Public Assessment Report Public Assessment Report Slovak 29-11-2007
Patient Information leaflet Patient Information leaflet Slovenian 24-06-2010
Summary of Product characteristics Summary of Product characteristics Slovenian 24-06-2010
Public Assessment Report Public Assessment Report Slovenian 29-11-2007
Patient Information leaflet Patient Information leaflet Finnish 24-06-2010
Public Assessment Report Public Assessment Report Finnish 29-11-2007
Patient Information leaflet Patient Information leaflet Swedish 24-06-2010
Public Assessment Report Public Assessment Report Swedish 29-11-2007
Patient Information leaflet Patient Information leaflet Norwegian 24-06-2010
Summary of Product characteristics Summary of Product characteristics Norwegian 24-06-2010
Patient Information leaflet Patient Information leaflet Icelandic 24-06-2010
Summary of Product characteristics Summary of Product characteristics Icelandic 24-06-2010

Search alerts related to this product

View documents history